An open label phase I study of fixed dose lapatinib in combination with an escalating dose of epirubicin in metastatic breast cancer

Trial Profile

An open label phase I study of fixed dose lapatinib in combination with an escalating dose of epirubicin in metastatic breast cancer

Completed
Phase of Trial: Phase I

Latest Information Update: 24 Jun 2016

At a glance

  • Drugs Lapatinib (Primary) ; Epirubicin
  • Indications Advanced breast cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 12 Feb 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 12 Feb 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top